Source: Reuters
Area: News
Reuter's reports that a United States Food and Drug Administration (FDA) advisory panel has supported ocriplasmin (Jetrea®) as a treatment for vitreomacular adhesion, an age-related vision problem that can lead to blindness. The panel concluded that ocriplasmin benefited enough people in clinical trials to warrant a favourable review, despite evidence of adverse effects including eye pain, swelling and blurred vision. Several panel members recommended further studies to monitor safety and determine more fully the drug's effectiveness.
The recommendations will now be considered by FDA regulators, (Read more...)
Uncategorized